PMID- 23232549
OWN - NLM
STAT- MEDLINE
DCOM- 20130226
LR  - 20240512
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Print)
IS  - 0009-9236 (Linking)
VI  - 93
IP  - 2
DP  - 2013 Feb
TI  - Clinical Pharmacogenetics Implementation Consortium guidelines for human 
      leukocyte antigen-B genotype and allopurinol dosing.
PG  - 153-8
LID - 10.1038/clpt.2012.209 [doi]
AB  - Allopurinol is the most commonly used drug for the treatment of hyperuricemia and 
      gout. However, allopurinol is also one of the most common causes of severe 
      cutaneous adverse reactions (SCARs), which include drug hypersensitivity 
      syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A variant 
      allele of the human leukocyte antigen (HLA)-B, HLA-B*58:01, associates strongly 
      with allopurinolinduced SCAR. We have summarized the evidence from the published 
      literature and developed peer-reviewed guidelines for allopurinol use based on 
      HLA-B genotype.
FAU - Hershfield, M S
AU  - Hershfield MS
AD  - Department of Medicine, Duke University School of Medicine, Durham, North 
      Carolina, USA.
FAU - Callaghan, J T
AU  - Callaghan JT
FAU - Tassaneeyakul, W
AU  - Tassaneeyakul W
FAU - Mushiroda, T
AU  - Mushiroda T
FAU - Thorn, C F
AU  - Thorn CF
FAU - Klein, T E
AU  - Klein TE
FAU - Lee, M T M
AU  - Lee MT
LA  - eng
GR  - U01 HL105198/HL/NHLBI NIH HHS/United States
GR  - R24 GM061374/GM/NIGMS NIH HHS/United States
GR  - GM61374/GM/NIGMS NIH HHS/United States
GR  - U01 GM061374/GM/NIGMS NIH HHS/United States
GR  - U01 GM092666/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, N.I.H., Extramural
DEP - 20121017
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
RN  - 0 (Gout Suppressants)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*58:01 antigen)
RN  - 63CZ7GJN5I (Allopurinol)
SB  - IM
MH  - Alleles
MH  - Allopurinol/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Genotype
MH  - Gout/drug therapy
MH  - Gout Suppressants/*administration & dosage/adverse effects
MH  - HLA-B Antigens/*genetics
MH  - Humans
MH  - Hyperuricemia/drug therapy
MH  - Pharmacogenetics
MH  - Stevens-Johnson Syndrome/chemically induced/etiology/*genetics
PMC - PMC3564416
EDAT- 2012/12/13 06:00
MHDA- 2013/02/27 06:00
PMCR- 2013/02/01
CRDT- 2012/12/13 06:00
PHST- 2012/12/13 06:00 [entrez]
PHST- 2012/12/13 06:00 [pubmed]
PHST- 2013/02/27 06:00 [medline]
PHST- 2013/02/01 00:00 [pmc-release]
AID - clpt2012209 [pii]
AID - 10.1038/clpt.2012.209 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 
      Oct 17.